Influence of Quinidine, Cimetidine, and Ketoconazole on the Enantioselective Pharmacokinetics and Metabolism of Metoprolol in Rats

被引:19
作者
Boralli, Vanessa Bergamin [1 ]
Coelho, Eduardo Barbosa [2 ]
Lanchote, Vera Lucia [1 ]
机构
[1] Univ Sao Paulo, Dept Clin Toxicol & Bromatol Anal, Fac Pharmaceut Sci Ribeirao Preto, BR-14040903 Ribeirao Preto, SP, Brazil
[2] Univ Sao Paulo, Dept Internal Med, Discipline Nephrol, Fac Med Ribeirao Preto, BR-14040903 Ribeirao Preto, SP, Brazil
基金
巴西圣保罗研究基金会;
关键词
metoprolol; cytochrome P450 inhibitors; metabolites; pharmacokinetics; rats; enantiomers; IN-VIVO; OXIDATIVE-METABOLISM; LIVER MICROSOMES; P-GLYCOPROTEIN; CYTOCHROME-P450; PLASMA; SUBFAMILY; 3A;
D O I
10.1002/chir.20682
中图分类号
R914 [药物化学];
学科分类号
100705 [微生物与生化药学];
摘要
Metoprolol is a beta-blocker and its racemic mixture is used for the treatment of hypertension. In the present study we investigated the influence of CYP2D and CYP3A on the stereoselective metabolism of metoprolol in rats. Male Wistar rats (n = 6 per group) received racemic metoprolol (15 mg/kg) orally, with or without pretreatment with the CYP inhibitor ketoconazole (50 mg/kg), cimetidine (150 mg/kg), or quinidine (80 mg/kg). Blood samples were collected up to 48 h after metoprolol administration. The plasma concentrations of the stereoisomers of metoprolol, O-demethylmetoprolol (ODM), alpha-hydroxymetoprolol (OHM) (Chiralpak(R) AD column), and metoprolol acidic metabolite (AODM) (Chiralcel(R) OD-R column) were determined by HPLC using fluorescence detection (lambda(exc) = 229 nm; lambda(em) = 298 nm). CYP3A inhibition by ketoconazole reduced the plasma concentrations of ODM and AODM and favored the formation of OHM. CYP2D and CYP3A inhibition by cimetidine reduced the plasma concentrations of OHM and AODM and favored the formation of ODM. The inhibition of CYP2D by quinidine reduced the plasma concentrations of OHM and favored the formation of ODM. In conclusion, the results suggest that CYP3A is involved in the formation of ODM and CYP2D is involved in the formation of AODM. Chirality 21:886-893, 2009. (C) 2009 Wiley-Liss, Inc.
引用
收藏
页码:886 / 893
页数:8
相关论文
共 21 条
[1]
Quantitative drug interactions prediction system (Q-DIPS) -: A dynamic computer-based method to assist in the choice of clinically relevant in vivo studies [J].
Bonnabry, P ;
Sievering, J ;
Leemann, T ;
Dayer, P .
CLINICAL PHARMACOKINETICS, 2001, 40 (09) :631-640
[2]
Stereoselective analysis of metoprolol and its metabolites in rat plasma with application to oxidative metabolism [J].
Boralli, VB ;
Coelho, EB ;
Cerqueira, PM ;
Lanchote, VL .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2005, 823 (02) :195-202
[3]
BORG KO, 1975, ACTA PHARMACOL TOX, V36, P116
[4]
Enantioselective determination of metoprolol acidic metabolite in plasma and urine using liquid chromatography chiral columns: applications to pharmacokinetics [J].
Cerqueira, PM ;
Boralli, VB ;
Coelho, EB ;
Lopes, NP ;
Guimaraes, LFL ;
Bonato, PS ;
Lanchote, VL .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2003, 783 (02) :433-441
[5]
COULBOURNE PD, 1997, J PHARM TOXICOL METH, V38, P27
[6]
INTERINDIVIDUAL VARIATION OF BETA-ADRENOCEPTOR BLOCKING-DRUGS, PLASMA-CONCENTRATION AND EFFECT - INFLUENCE OF GENETIC STATUS ON BEHAVIOR OF ATENOLOL, BOPINDOLOL AND METOPROLOL [J].
DAYER, P ;
LEEMANN, T ;
MARMY, A ;
ROSENTHALER, J .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1985, 28 (02) :149-153
[7]
In vivo effects of cyclosporin A and ketoconazole on the pharmacokinetics of representative substrates for P-glycoprotein and cytochrome P450 (CYP) 3A in rats [J].
Kageyama, M ;
Namiki, H ;
Fukushima, H ;
Ito, Y ;
Shibata, N ;
Takada, K .
BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2005, 28 (02) :316-322
[8]
Law MYL, 2000, DRUG METAB DISPOS, V28, P348
[9]
Levine M, 1998, J PHARMACOL EXP THER, V284, P493
[10]
Comparison of CYP2D6 content and metoprolol oxidation between microsomes isolated from human livers and small intestines [J].
Madani, S ;
Paine, MF ;
Lewis, L ;
Thummel, KE ;
Shen, DD .
PHARMACEUTICAL RESEARCH, 1999, 16 (08) :1199-1205